Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pemetrexed-associated urticarial vasculitis.

Gilberto Lopes1, Vladimir Vincek, Luis E Raez

  • 1Division of Hematology/Oncology, Sylvester Cancer Center, University of Miami Miller School of Medicine, Fl, USA.

Lung Cancer (Amsterdam, Netherlands)
|December 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.

Immunotherapy·2026
Same author

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

International journal of molecular sciences·2026
Same author

Tarlatamab in Previously Treated Small Cell Lung Cancer: A Real-World Experience in a Predominantly Hispanic Population with CNS Metastases.

Cancers·2026
Same author

Geographic, Temporal, and Sex-Specific Trends in Mesothelioma Burden in the United States, 1990-2023.

JCO global oncology·2026
Same author

Synergistic senolytic-regenerative therapy significantly extends healthspan and lifespan.

Journal of translational medicine·2026
Same journal

ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Corrigendum to "European experience on oncological outcomes of patients with early stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" [Lung Cancer J. 217 (2026) 109410].

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Proportion of lung cancer patients eligible for screening in France: Data from the KBP-2020-CPHG study.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Prognostic impact of the 9th vs 8th TNM classification in small-cell lung cancer. a population-based study.

Lung cancer (Amsterdam, Netherlands)·2026
See all related articles

Pemetrexed, an anti-folate drug, can cause skin rash. This case report details a patient experiencing urticarial vasculitis as a pemetrexed-induced rash.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Pemetrexed is a novel anti-folate agent approved for malignant pleural mesothelioma and non-small cell lung cancer.
  • Phase III trials reported rash in 17-22% of patients receiving pemetrexed.
  • Limited data exists on the characteristics and mechanisms of pemetrexed-induced rash.

Observation:

  • A patient treated with pemetrexed developed a distinct skin rash.
  • The rash was characterized as urticarial vasculitis.

Findings:

  • The observed rash was directly associated with pemetrexed treatment.
  • Urticarial vasculitis is identified as a potential mechanism for pemetrexed-induced dermatopathy.

Implications:

Related Experiment Videos

  • This case expands understanding of pemetrexed's adverse dermatological effects.
  • Further research into pemetrexed-associated rash mechanisms is warranted.
  • Clinicians should consider urticarial vasculitis in patients developing rash during pemetrexed therapy.